AUS
NZ
UK
CA
USA
IND
Immuron Ltd (ASX:IMC) has received positive feedback from the United States Food and Drug Administration (FDA) regarding its IMM-529 product, aimed at preventing or treating Clostridioides difficile infection (CDI). This feedback follows a pre-IND (Investigational New Drug) meeting with the FDA and supports the ongoing development of IMM-529.
Addressing an Unmet Need
The rise in antibiotic-resistant 'superbugs' has led to increased use of broad-spectrum antibiotics, which disrupts the gastrointestinal microbiota and makes individuals more susceptible to opportunistic pathogens like C. difficile. Treating CDI often involves antibiotics, which can disrupt gut flora further and lead to recurrent infections. C. difficile is a significant pathogen in healthcare-associated infections and has been identified as an urgent threat by the Centers for Disease Control and Prevention (CDC). CDI affects over 400,000 people annually in the US, contributing to more than 30,000 deaths. This situation underscores the urgent need for new therapies that could reduce or replace antibiotic use for bacterial infections.
To address this, Immuron is developing IMM-529 as an adjunctive therapy to be used with standard antibiotics for preventing and treating recurrent CDI. IMM-529 aims to target C. difficile with specific antibodies, which could help clear the infection and support the restoration of normal gut flora, offering a potential oral preventative for recurrent CDI.
Investigational New Drug (IND) Application
Following the FDA’s guidance, Immuron plans to file an IND application for IMM-529 in the first half of 2025, which will be followed by a Phase 2 trial involving individuals with CDI. The company is collaborating with Dr. Dena Lyras and her team at Monash University in Australia to develop vaccines that produce bovine colostrum-derived antibodies. These antibodies target three key components of C. difficile: Toxin B (TcB), the spores, and surface layer proteins of vegetative cells. This multi-target approach has shown promising results in pre-clinical models.
Market Potential
An opportunity assessment by Lumanity suggests that if IMM-529 proves effective, it could be positioned early in treatment algorithms, with a potential market for patients experiencing recurrent CDI. Immuron estimates that approximately 31,000 patients could be eligible if IMM-529 is used for second recurrences, and up to 95,000 patients could be eligible if used for first recurrences. Based on these estimates, the potential annual revenue for IMM-529 is projected at around US$93 million, with possible increases if the product is used more broadly.
This promising development highlights the potential impact of IMM-529 on addressing a critical healthcare need and advancing Immuron’s goals in the global market.
